PACS (NYSE: PACS) CEO sells 36,692 shares in a trading plan sale

Posted by Francis Steltz on Oct 9th, 2026

What happened

PACS Group, Inc. (NYSE: PACS) said Jason Hulse Murray, the co-founder, CEO and chairman, and a director and 10% owner, sold 36,692 shares on 10/06/2026 and 10/07/2026. The filing says the trades were made under a Rule 10b5-1 trading plan adopted on May 18, 2026. The filing covers open-market common stock sales.

The filing lists three sales. Murray sold 28,753 shares at a weighted average $42.9554, 7,222 shares at $43.637 and 717 shares at $42.48. The first two sales were on 10/06/2026, and the last was on 10/07/2026. After the trades, Murray held 54,435,249 shares, and Table II shows no derivative securities activity.

Key numbers

Metric	Latest	Source
Shares sold	36,692 shares	SEC Form 4
Sale price	from $42.48 to $43.64 per share	SEC Form 4
Total value	about $1.58 million	SEC Form 4
Shares held after sale	54,435,249 shares	SEC Form 4

Read more: PACS Group (PACS) stock analysis and investment case

Why it matters

OptimistFi's case is that PACS can compound if its independently operated facility model keeps turning post-acute demand into profitable cash flow despite labor, reimbursement and regulatory pressure. This Form 4 is about ownership, not operations. The 36,692 shares were about 0.1% of Murray's holding before the trade, so the sale is small compared with the stake that remains.

Murray still held 54,435,249 shares after the sale, so the position remains large. The shares were sold at prices from $42.48 to $43.64 per share, and the total value was about $1.58 million. The remaining stake still leaves Murray closely tied to PACS results.

The main caveat is the Rule 10b5-1 plan, which the filing says Murray adopted on May 18, 2026. That makes the trade less useful as a fresh read on sentiment. It is the clearest limit on what this filing says.

Browse: stock research on every company OptimistFi covers

What's next

PACS Group, Inc.'s next quarterly report is the next test for the thesis. Better operating results or cash generation would support OptimistFi's case. Weakness would leave this filing as a trading-plan sale and little else. The next report will matter more than the sale itself.

If the next report shows stronger cash generation, it would strengthen the consolidation-and-operations thesis. If it does not, the trade will stay a small footnote. That is the cleanest follow-up investors will have from this Form 4.